References
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington (DC): American Psychiatric Association; 2013.
- Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;170(8):834–851.
- Auriacombe M, Serre F, Denis C, et al. Chapter 10. Diagnosis of addictions. In: Pickard H, Ahmed S, editors. The Routle. 1. Abingdon: Routledge; 2017 Jun 1. p. 500.
- Serre F, Fatseas M, Swendsen J, et al. Ecological momentary assessment in the investigation of craving and substance use in daily life: A systematic review. Drug Alcohol Depend. 2015;148:1–20.
- Auriacombe M, Serre F, Fatseas M. Le craving : marqueur diagnostique et pronostique des addictions? In: Reynaud M, Benyamina A, Karila L, et al., editors. Traité d’addictologie. Paris: Lavoisier; 2016. p. 78–83.
- Torrens M, Domingo-Salvany A, Alonso J, et al. Methadone and quality of life. Lancet [Internet]. 1999;353:1101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10199379
- Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ [Internet]. 2017;j1550. DOI:10.1136/bmj.j1550.
- Barry DT, Savant JD, Beitel M, et al. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict. 2013. 22(3):212–217.
- College of Physicians and Surgeons of British Columbia. Methadone and buprenorphine: clinical practice guideline for opioid use disorder. Vancouver, BC; 2016. [cited 27 Nov]. Available from: https://www.divisionsbc.ca/CMSMedia/Divisions/DivisionCatalog-nanaimo/Documents/Substance%20Use/Resources/Opiod/MBMT-Clinical-Practice-Guideline.pdf
- College of Physicians and Surgeons of Saskatchewan. Saskatchewan methadone guidelines and standards for the treatment of opioid addiction/dependence. Saskatchewan; 2015. [cited 27 Nov]. Available from: https://www.cps.sk.ca/imis/Documents/Programs%20and%20Services/Methadone/SK-Methadone-Guidelines-2015-Mar-FINAL.pdf
- Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
- Nice TA 114 Methadone and buprenorphine for the management of opioid dependence. 2007; Available from: https://www.nice.org.uk/guidance/ta114/resources/methadone-and-buprenorphine-for-the-management-of-opioid-dependence-82598072878789
- Advisory Council on the Misuse of Drugs (ACMD). How can opioid substitution therapy (and drug treatment and recovery systems) be optimised to maximise recovery outcomes for service users? London; 2015. [cited 27 Nov]. Available from: http://www.rcpsych.ac.uk/pdf/ACMD_RC_OPTIMISING_OST_REPORT_231015.pdf
- Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence. Drug misuse and dependence: UK guidelines on clinical management. London; 2017. [cited 27 Nov]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628634/clinical_guidelines_2017.pdf
- Carroll K, Weiss R. The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry. 2017;174(8):738–747.
- Dugosh K, Abraham A, Seymour B, et al. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med [Internet]. 2016;10(2):93–103. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01271255-201604000-00004
- Day E, Mitcheson L. Psychosocial interventions in opiate substitution treatment services: does the evidence provide a case for optimism or nihilism? Addiction. 2017;112(8):1329–1336.
- Ministry of Health. New Zealand practice guidelines for opioid substitution treatment. Wellington; 2014. [cited 27 Nov]. Available from: https://www.health.govt.nz/system/files/documents/publications/nz-practice-guidelines-opioid-substitution-treatment-apr14-v2.pdf
- Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;(10). Art. No.: CD004147. DOI: 10.1002/14651858.CD004147.pub4.
- Roncero C, Barral C, Rodríguez-Cintas L, et al. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Psychiatry Res [Internet]. 2016;243:174–181.
- Goldner EM, Lusted A, Roerecke M, et al. Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses. Addict Behav [Internet]. 2014;39(3):520–531.
- Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28:388–406.
- Mangrum LF, Spence RT, Lopez M. Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. J Subst Abuse Treat. 2006;30(1):79–84.
- Torrens M, Rossi PC, Martinez-Riera R, et al. Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse [Internet]. 2012;47(8–9):1005–1014. Available from: http://www.tandfonline.com/doi/full/10.3109/10826084.2012.663296
- SAMHSA. Chapter 2. History of medication-assisted treatment for opioid addiction. In: medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. Rockville; 2005. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64157/
- European Monitoring Centre for Drugs and Drug Addiction. EMCDDA | legal frameworks of opioid substitution treatment [Internet]. 2008 [cited 2017 Nov 8]. Available from: http://www.emcdda.europa.eu/html.cfm/index41823EN.html
- Van Den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006;51(10):635–646.
- EMCDDA. Annual report on the state of the drugs problem in the European Union. Chapter 4 Selected issue: Substitution treatment [Internet]. 2000. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_37235_EN_sel00_1en.pdf
- Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358–364.
- Medicines and Healthcare Regulatory Agency. Summary of product characterstics - Subutex 0.4mg sublingual tablets [Internet]. London; 1998. Available from: http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1507872154598.pdf
- Committee for Medicinal Products for Human Use (EMA). Assessment report - Suboxone [Internet]. Vol. EMA/774165. London; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000697/WC500198036.pdf
- Metz VE, Brandt L, Unger A, et al. Substance abuse/dependence treatment: A European perspective. Subst Abus. 2014;35(3):309–320.
- Brandt L, Unger A, Moser L, et al. Opioid maintenance treatment - A call for a joint European quality care approach. Eur Addict Res. 2016;22(1):36–51.
- European Monitoring Centre for Drugs and Drug Addiction. Health and social responses to drug problems [Internet]. Luxembourg; 2017. Available from: http://www.emcdda.europa.eu/system/files/publications/6343/TI_PUBPDF_TD0117699ENN_PDFWEB_20171009153649.pdf
- Degenhardt L, Glantz M, Evans-Lacko S, et al. Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. World Psychiatry. 2017;16(3):299–307.
- EMCDDA. Annual report 2010: the state of the drugs problem in Europe [Internet]. Luxembourg; 2010. Available from: http://www.emcdda.europa.eu/system/files/publications/926/EMCDDA_AR2010_EN_242720.pdf
- World Health Organization. How to improve opioid substitution therapy implementation [Internet]. Copenhagen; 2014. Available from: http://www.euro.who.int/__data/assets/pdf_file/0015/241341/How-to-improve-Opioid-Substitution-Therapy-implementation.pdf?ua=1:
- Gowing L, Ali R, Dunlop A, et al. National guidelines for medication-assisted treatment of opioid dependence. Canberra: Commonwealth of Australia; 2014. [cited 27 Nov]. Available from: http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/Publishing.nsf/content/AD14DA97D8EE00E8CA257CD1001E0E5D/$File/National_Guidelines_2014.pdf
- Vancouver Coastal Health & Providence, Health Care Opioid Use Disorder. A guideline for the clinical management of opioid addiction [Internet]. 2015. Available from: http://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/evidence-based-approaches-to-drug-addiction-treatment/pharmacotherapies
- Departement for the Treatment of Substance Abuse. Policy of the department for the treatment of substance abuse: treatment of opioid addiction through psychosocial therapy and maintenance treatment (agonists and partial agonists such as: methadone, buprenorphine/buprenorphine/naloxone). Jerusalem: Department for the Treatment of Substance Abuse; 2017.
- The Swedish National Board of Health and Welfare (Support for governance and management). National guidelines for care and support in cases of misuse and addiction. Stockholm: The Swedish National Board of Health and Welfare; 2016.
- Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367.
- Waller R. Medication Assisted Treatment (MAT) guidelines for opioid use disorders [Internet]. Michigan; 2014. Available from: http://www.michigan.gov/documents/mdhhs/MAT_Guidelines_for_Opioid_Use_Disorders_524339_7.pdf
- WHO. Guidelines for the identification and management of substance use and substance use disorders in pregnancy [Internet]. 2014. Available from: www.who.int/substance_abuse
- College of Psychiatrists in Ireland. Clinical guidelines for opioid substitution treatment. Heal Serv Exec [Internet]. 2016. Available from: http://hse.ie/eng/services/publications/Primary/clinical-guidelines-for-opioid-substitution-treatment.pdf
- Baxter LE, Campbell A, Deshields M, et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med [Internet]. Jan [cited 2016 Feb 15];7(6):377–386. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24189172
- Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone - Implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–1193.
- Trafton JA, Minkel J, Humphreys K. Determining effective methadone doses for individual opioid-dependent patients. PLoS Med. 2006;3(3):380–387.
- Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253–263.
- Meesmann U, Boets S, Alvarez FJ, et al. Main DRUID results to be communicated to different target groups. 2011. [cited 27 Nov]. Available from: http://orbit.dtu.dk/files/6444004/Deliverable_7_3_2.pdf
- Maxwell S, Shinderman M. Optimizing response to methadone maintenance treatment: use of higher-dose methadone. J Psychoactive Drugs. 1999;31(2):95–102.
- Maremmani I, Shinderman M. Alcohol, benzodiazepines and other drugs use in heroin addicts treated with methadone. Polyabuse or undermedication? Heroin Addict Relat Clin Probl. 1999;1(2):7–13.
- Gorzelańczyk EJ, Fareed A, Walecki P, et al. Risk behavior in opioid-dependent individuals after the administration of a therapeutic dose of methadone. Am J Addict. 2014;23(6):608–612.
- Swift RM, Stout RL. The relationship between craving, anxiety, and other symptoms in opioid withdrawal. J Subst Abuse. 1992;4(1):19–26.
- Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol. 2005;5(1):9–19.
- Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci. 2012;1248(1):1–17.
- Leavitt SB, Shinderman M, Maxwell S, et al. When “enough” is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med [Internet]. 2000;67(5–6):404–411. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11064491
- De Vos JW, Ufkes JGR, Van Brussel GHA, et al. Craving despite extremely high methadone dosage. Drug Alcohol Depend. 1996;40(3):181–184.
- Maremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention during treatment of heroin addicts with axis I psychiatric comorbidity. J Addict Dis [Internet]. 2000;19(2):29–41. Available from: http://www.tandfonline.com/doi/pdf/10.1300/J069v19n02_03?needAccess=true
- Elkader AK, Brands B, Selby P, et al. Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol. 2009;29(3):231–238.
- Wahawisan J, Kolluru S, Nguyen T, et al. Methadone toxicity due to smoking cessation-a case report on the drug-drug interaction involving cytochrome p450 isoenzyme 1a2. Ann Pharmacother. 2011;45(6):34.
- Talka R, Salminen O, Tuominen RK. Methadone is a non-competitive antagonist at the a4b2 and a3* nicotinic acetylcholine receptors and an agonist at the a7 nicotinic acetylcholine receptor. Basic Clin Pharmacol Toxicol. 2015;116(4):321–328.
- Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617–626.
- Verthein U, Beck T, Haasen C, et al. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res. 2015;21(2):97–104.
- Ferri M, Minozzi S, Bo A, et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev [Internet]. 2013;(6). Available from: http://doi.wiley.com/10.1002/14651858.CD009879.pub2
- Walton G, Nolan S, Sutherland C, et al. Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest. BMJ Case Rep [Internet]. 2015;bcr2015210239. Available from: http://casereports.bmj.com/lookup/doi/10.1136/bcr-2015-210239
- Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661–680.
- Methadone Treatment and Services Advisory Committee. Methadone treatment and services advisory committee final report. Ontario: Ministry of Health and Long-Term Care. Methadone Treatment and Services Advisory Committee; Jun 2016. [cited 27 Nov]. Available from: http://health.gov.on.ca/en/public/programs/drugs/ons/docs/methadone_advisory_committee_report.pdf.
- Orman JS, Keating GM, Renzelli CM, et al. Buprenorphine/Naloxone a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577–607.
- Soyka M. Buprenorphine use and risk of abuse and diversion. Adv Pharmacoepidemiol Drug Saf [Internet]. 2014;3(1). Available from: http://www.omicsgroup.org/journals/2167-1052/2167-1052-abstract.php?abstract_id=22419
- Accurso AJ, Rastegar DA. The effect of a payer-mandated decrease in buprenorphine dose on aberrant drug tests and treatment retention among patients with opioid dependence. J Subst Abuse Treat. 2016;61:74–79.
- Soyka M, Hillemacher T. Commentary on Hser, et al. 2014. To retain or not to retain — open questions in opioid maintenance therapy. Addiction. 2014;109(1):88–89.
- Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to Buprenorphine/Naloxone compared to methadone in A multi-site trial. Natl Inst Heal. 2014;109(1):79–87.
- Greenwald MK, Schuh KJ, Hopper JA, et al. Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berl). 2002;160(4):344–352.
- Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology [Internet]. 2003;28(11):2000–2009. Available from: http://www.nature.com/doifinder/10.1038/sj.npp.1300251
- Greenwald M, Comer S, Fiellin D. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;1:1–11.
- Maremmani I, Rolland B, Somaini L, et al. Buprenorphine dosing choices in specific populations: review of expert opinion. Expert Opin Pharmacother [Internet]. 2016;17(13):1727–1731.
- Heikman PK, Muhonen LH, Ojanperä IA. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psychiatry [Internet]. 2017;17(1):245. Available from: http://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-017-1415-y
- Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev [Internet]. 2014;2(2):CD002207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24500948
- Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87.
- Canadian Agency for Drugs and Technologies in Health. Buprenorphine/naloxone versus methadone for the treatment of opioid dependence: a review of comparative clinical effectiveness, cost-effectiveness and guidelines. 2016. Available from: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0089424/pdf/PubMedHealth_PMH0089424.pdf
- Curcio F, Franco T, Topa M, et al. Buprenorphine/naloxone versus methadone in opioid dependence : a longitudinal survey. Eur Rev Med Pharmacol Sci. 2011;15(8):871–874.
- Chiappelli J, Chen S, Hackman A, et al. Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population. Schizophr Res [Internet]. 2017; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0920996417302633
- Tenore P. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49–65.
- Panin P, Maremmani I, Pacini M, et al. Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res. 2011;17(2):80–89.
- Parvaresh N, Masoudi A, Majidi-Tabrizi S, et al. The correlation between methadone dosage and comorbid psychiatric disorders in patients on methadone maintenance treatment. Addict Heal. 2012;4(1–2):1–8.
- Sher L. The role of the endogenous opioid system in the pathogenesis of anxiety disorders. Med Hypotheses. 1998;50(6):473–474.
- Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(10):793–802.
- Maremmani AGI, Rovai L, Pani PP, et al. Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry [Internet]. 2011;10(17). Available from: http://www.annals-general-psychiatry.com/content/10/1/17
- Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195–206.
- Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.
- Butelman ER, Yuferov V, Kreek MJ. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012;35(10):587–596.
- National Institute on Drug Abuse (NIDA). National overdose deaths - number of deaths from benzodiazepines. [Internet]. 2017 [cited 2017 Nov 8]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates
- Nolan S, Klimas J, Wood E. Alcohol use in opioid agonist treatment. Addict Sci Clin Pract [Internet]. 2016;11(1):17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27931253%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5146864
- Soyka M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78–87.
- FDA. Opioid addiction medications in patients taking benzodiazepines or CNS Depressants : drug safety communication - careful medication management can reduce risks. Silver Spring: FDA (U S Food and Drug Administration); 2017. [cited 27 Nov]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM576377.pdf
- Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125(1–2):8–18.
- Nava F, Manzato E, Leonardi C, et al. Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study. Prog Neuropsychopharmacol Biol Psychiatry [Internet]. 2008;32(8):1867–1872. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18801404
- Tetrault JM, McCance-Katz EF, Moody DE, et al. The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without hiv-infection. J Subst Abuse Treat. 2015;51:70–74.
- McCance-Katz EF, Jatlow P, Rainey PM. Effect of cocaine use on methadone pharmacokinetics in humans. Am J Addict. 2010;19(1):47–52.
- McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict. 2010;19(1):38–46.
- Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75(1):34–38.
- Ling W, Hillhouse MP, Saxon AJ, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016;111(8):1416–1427.
- McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16.
- Nielsen S, Degenhardt L, Larance B, et al. Opioid agonist treatment for pharmaceutical opioid dependent people (Protocol) [Internet]. Cochrane Databse Systematic Reveiws. 2016; Available from: https://static1.squarespace.com/static/57b13af320099e871dd94dc8/t/57c31e98be6594ea1c74f802/1472405153331/2016+cochrane+replacement.pdf
- Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA [Internet]. 2017;317(9):967–968. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2017.0001%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/28267837
- Javaher S, Mai J. Interagency guideline on prescribing opioids for pain. J Pain. 2015;(Jun):1–105.
- Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107(SUPPL.1):63–73.
- World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. WHO Press: Geneva; 2009.
- Auriacombe M, Dubernet J, Sarram S, et al. Traitements pharmacologiques dans les addictions : pour une approche transversale et simplifiée. In: Reynaud M, Benyamina A, Karila L, et al., editors. . Traité d’addictologie. Paris: Lavoisier;; 2016. p. 307–310.
- Substance abuse and mental health services administration. Medication-assisted treatment for opioid addiction in opioid treatment programs [Internet]. 2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK64164/%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22514849
- National collaborating centre for mental health (UK). Drug misuse: opioid detoxification [Internet]. British Psychological Society. British Psychological Society; 2008. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21452460
- Fischer G, Nava F, Stover H. Outcomes of opioid-dependence treatment across Europe: identifying opportunities for improvement. Heroin Addict Relat Clin Probl. 2012;14(4):39–50.
- Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane Database Syst Rev. 2017;2017(4):4–6.